Janssen submits sBLA to FDA for NSCLC combination therapy

The Janssen has submitted a sBLA to the US FDA for RYBREVANT plus chemotherapy for non-small cell lung cancer (NSCLC).

Aug 28, 2023 - 20:00
Janssen submits sBLA to FDA for NSCLC combination therapy
The Janssen has submitted a sBLA to the US FDA for RYBREVANT plus chemotherapy for non-small cell lung cancer (NSCLC).

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow